ANAPC1

Across TCGA pan-cancer cohorts, ANAPC1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANAPC1 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANAPC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANAPC1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where ANAPC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.982	0.794	.002	23	view →
LSCC	DFS	Median	II,III,IV	0.886	0.534	.004	11	view →
PDAC	OS	Median	II,III,IV	0.424	0.619	.007	8	view →
HNSC	OS	Tertile	III,IV	0.792	0.512	.008	8	view →
CCRCC	OS	Tertile	All	0.925	0.766	.032	2	view →
GBM	DFS	Median	All	0.434	0.314	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANAPC1–LUAD (DFS)

Open the LUAD breakdown →